|All Peptides

Liraglutide

Last reviewed: April 18, 2026 by The Peptide Catalog Team

An FDA-approved daily weight loss injection with the longest safety track record. Liraglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes and weight management. The first GLP-1 approved for weight loss, it produces 5-10% body weight reduction. Requires daily injection due to its ~13 hour half-life, but has the longest safety track record among GLP-1 medications.

Overview

Liraglutide Results Timeline

Progression
1
Week 1–4
Physical Changes
Gradual weight loss begins (1-3 lbs), appetite reduction
Performance & Recovery
Moderate appetite suppression, learning new eating patterns
Other Benefits
Dose titration period, mild GI effects possible
2
Month 2–3
Physical Changes
Steady weight loss (4-7%), visible changes
Performance & Recovery
Consistent appetite control, easier portion management
Other Benefits
Blood sugar improvements, stable energy
3
Month 4–6
Physical Changes
Continued weight reduction (7-10%), improved body composition
Performance & Recovery
Physical activity more comfortable, better endurance
Other Benefits
Cardiovascular benefits emerging, metabolic improvements
4
6+ Months
Physical Changes
5-10% total weight loss maintained
Performance & Recovery
Sustained benefits with daily dosing adherence
Other Benefits
Long-term cardiovascular protection, established weight management

Timeline is illustrative and non-guaranteed. Outcomes vary and are commonly discussed alongside training, nutrition, sleep, and cycling practices.

Evidence at a glance

Two parallel grades per outcome — clinical RCT depth and real-world community adoption. See the Research Overview below for citations and detail.

OutcomeClinical EvidenceCommunity Evidence
Body weight reduction (obesity)StrongModerate
HbA1c reduction in T2DStrongModerate
Cardiovascular event reductionStrongModerate
Adolescent obesityStrongModerate
How It WorksGLP-1 Receptor Agonist — Daily Incretin Mimetic

Receptor → Metabolic Cascade → Weight & Glucose → Outcomes

1
Target

GLP-1 Receptors (Pancreas, Brain, Gut)

Liraglutide targets the same GLP-1 receptors as semaglutide, but with a shorter half-life (~13 hours vs 7 days). This means daily injection instead of weekly, but allows finer dose control and faster washout if side effects occur.

2
Cellular Signal

cAMP/PKA → Insulin Secretion + Appetite Suppression

Same GLP-1 receptor signaling cascade as semaglutide — insulin release tied to blood sugar levels, central satiety activation, and slowed gastric emptying. The daily dosing provides more physiological GLP-1 receptor stimulation compared to weekly agents.

3
Systemic Effect

Appetite Reduction + Glucose Control → Weight Loss

Clinical trials show ~8% body weight loss (vs 15-20% for semaglutide). Cardiovascular benefits demonstrated in the LEADER trial. The first GLP-1 to receive weight-loss approval (2014).

4
What You Notice

Moderate Appetite Reduction → Steady Weight Loss

Appetite suppression noticeable within days. Weight loss is moderate but consistent. GI side effects similar to semaglutide but may resolve faster due to daily dosing flexibility. Good starting point before transitioning to weekly agents if needed.

What Makes This Peptide Different

Liraglutide was the first GLP-1 approved for weight loss (prescription weight management). Its daily dosing is less convenient than weekly semaglutide, but allows more precise titration and faster washout if side effects occur. Some prefer starting with liraglutide to gauge GLP-1 tolerance before switching to a weekly agent.

Research overview

Outcome-by-outcome look at what the evidence actually supports for Liraglutide, including human vs. animal study counts and our editorial take on each.

Body weight reduction in obesity

Clinical:StrongCommunity:Moderate

Pi-Sunyer 2015 (SCALE Obesity, n=3731) showed liraglutide 3.0 mg daily produced 8.0% mean weight loss vs 2.6% placebo over 56 weeks in adults without diabetes. Effect is meaningful but smaller than semaglutide and tirzepatide — and daily injection requirement vs weekly is a significant tolerability disadvantage.

5 human studies · 6 animal studies

Key findings & citations
  • SCALE: 8.0% weight loss vs 2.6% placebo at 56 weeks.
  • 63.2% of treated patients achieved ≥5% weight loss vs 27.1% placebo.
  • Daily injection schedule disadvantages it vs weekly semaglutide / tirzepatide.

Our take

First-generation GLP-1 for obesity. Eclipsed by semaglutide and tirzepatide on efficacy and dosing convenience.

Cardiovascular outcomes in T2D

Clinical:StrongCommunity:Moderate

LEADER (Marso 2016, n=9340) showed 13% reduction in 3-point MACE in patients with T2D and high CV risk, with concurrent reductions in CV death and all-cause mortality. This was the first GLP-1 CV outcome trial to demonstrate superiority — establishing the class effect.

1 human study · 4 animal studies

Key findings & citations
  • LEADER: HR 0.87 for 3-point MACE (p=0.01 superiority).
  • Significant reductions in CV death and all-cause mortality.
  • Drove inclusion of GLP-1 agents in ADA/EASD T2D + CVD guidelines.

Our take

The trial that opened the GLP-1 cardiovascular era. Clinically, semaglutide has now eclipsed it on absolute efficacy.

Adolescent obesity

Clinical:StrongCommunity:Moderate

Kelly 2020 (NEJM, n=251) showed liraglutide 3.0 mg daily reduced BMI standard-deviation score significantly more than placebo over 56 weeks in adolescents 12-17 with obesity. This was the first FDA approval for pharmacological pediatric obesity treatment in this age group.

1 human study · 0 animal studies

Key findings & citations
  • Significant BMI-SDS reduction vs placebo in 12-17 year olds.
  • Led to FDA approval for adolescent obesity (the first GLP-1 in this population).
  • GI side effects mirror adult profile.

Our take

First peptide-class agent approved for adolescent obesity. Bridge to longer-term semaglutide use as patients age out of pediatric care.

What Liraglutide doesn't do

Claims that current evidence does not support. Worth knowing before you set expectations.

Where to Buy Liraglutide

Compare Liraglutide vendors →

Liraglutide is priced per vial, not per mg — see vetted vendors and per-vial pricing in the Liraglutide buying guide.

Dosing ProtocolWeight Loss / Diabetes

Educational reference only. Individual responses vary. Consult healthcare provider before use.

Vial Size
18 mg (pen)
Reconstitution
Pre-mixed pen
Dose
Start 0.6 mg, titrate to 3 mg daily
Timing
AM (same time daily)
Frequency
Daily
Duration
Long-term
Protocol Notes
Daily injection unlike weekly semaglutide. Titrate: 0.6mg week 1, then +0.6mg each week to 3mg.

Why This Dosing Protocol

Why daily?Liraglutide's ~13 hour half-life requires daily injection for consistent effect. This is its main disadvantage vs weekly semaglutide, but also its advantage — stop dosing and side effects resolve within 1-2 days.

Why slow titration? Same principle as all GLP-1s: start at 0.6mg, increase by 0.6mg each week up to 3mg. Minimizes nausea and GI discomfort.

Storage & Handling

Storage at a glance

Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.

Powder: Freezer
1+ year at -20°C
Reconstituted: Fridge
4 weeks max at 2-8°C
View Complete Storage Guide

Handling specifics

Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.

Powder storage (very stable)
  • Freezer (-20°C): 1+ year
  • Refrigerator (2-8°C): 1-3 months
  • Room temperature: 2-3 weeks (emergency only)
Reconstituted storage (fragile)
  • MUST refrigerate at 2-8°C
  • 4-week maximum shelf life
  • NEVER freeze after reconstitution
  • Use bacteriostatic water for multi-dose
Molecular Structure

Liraglutide sequence

Click any residue to see its properties.

HydrophobicPolarAcidic (−)Basic (+)Special

Sequence-derived properties

Length
31 residues
Molecular weight
3383.7 Da
backbone only
Avg hydrophobicity
-0.25
Kyte–Doolittle scale

Residue classes

Hydrophobic: 12 (39%)Polar: 7 (23%)Acidic (−): 4 (13%)Basic (+): 4 (13%)Special: 4 (13%)

Net charge distribution

Positive4 (13%)
Neutral23 (74%)
Negative4 (13%)

Amino acid frequency

A×4G×4E×3S×3F×2L×2R×2T×2V×2D×1

Modifications

  • C16 palmitoyl fatty acid at Lys26 via γ-glutamate spacer

Sequence and properties provided for educational reference. Not for clinical dosing decisions.

  • Length: 31 amino acids
    (97% identical to native GLP-1.)
  • Half-life: ~13 hours
    (Requires daily dosing.)
  • Mechanism: GLP-1 agonist
    (Incretin mimetic.)
  • Primary Use: Weight loss
    (5-10% body weight reduction.)
Key modification
C16 fatty acid (palmitic acid) at Lys²⁶
The palmitic acid side chain binds to albumin, protecting liraglutide from DPP-4 degradation. First GLP-1 approved for weight management with the longest safety track record.
Key takeaway: Liraglutide provides moderate weight loss with daily dosing. Its long safety history makes it a well-studied option, though newer weekly GLP-1s offer more convenience and efficacy.

FAQ

How does liraglutide compare to newer GLP-1 medications?

Liraglutide was the first GLP-1 approved for weight management. It produces 5-10% weight loss — effective but less than newer options like semaglutide (15-20%) or tirzepatide (20-25%). However, it has the longest safety track record and may be preferred for patients who want an established option or don't tolerate newer medications.

Why does liraglutide require daily injections?

Liraglutide has a half-life of about 13 hours, requiring once-daily injection. Newer medications like semaglutide were engineered with modifications that extend half-life to ~7 days, allowing weekly dosing. Despite the daily requirement, some patients prefer the flexibility of daily dose adjustment.

What are the common side effects?

The most common side effects are gastrointestinal: nausea (especially when starting), diarrhea, constipation, and vomiting. These typically diminish over time. The gradual dose titration schedule (starting at 0.6mg and increasing weekly) helps minimize GI effects. Rare serious risks include pancreatitis and gallbladder disease.

Is liraglutide still a good choice for weight loss?

Yes, liraglutide remains a valid option, especially for patients who prefer an established medication with a long safety record, need daily dosing flexibility, or don't respond well to newer alternatives. It's also sometimes more accessible due to insurance coverage or cost considerations.

What is the typical liraglutide dosing schedule?

Liraglutide for weight loss starts at 0.6mg daily for one week, then increases weekly by 0.6mg increments until reaching the target dose of 3.0mg daily. This 5-week titration helps minimize nausea. The injection can be given at any time of day, with or without food.

Is liraglutide FDA approved?

Yes, liraglutide is FDA-approved under two brand names: two indications: type 2 diabetes (up to 1.8mg) and weight management (up to 3.0mg). It was the first GLP-1 receptor agonist approved specifically for chronic weight management (2014), giving it over a decade of clinical use data.

How much weight can I expect to lose on liraglutide?

Clinical trials showed average weight loss of 5-8% of body weight over one year at the 3.0mg dose. About one-third of patients lose over 10%. While less than newer medications, this is still clinically meaningful and can significantly improve metabolic health markers.

Can liraglutide be switched to semaglutide?

Yes, patients can transition from liraglutide to semaglutide if seeking greater weight loss or preferring weekly dosing. The switch is typically done by stopping liraglutide and starting semaglutide at the initial dose, then titrating up. Consult your healthcare provider for appropriate transition timing.

How long does reconstituted peptide last?

Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.

Is this peptide legal to purchase?

Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.

New to peptides?

Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.

Scientific Sources

The following peer-reviewed studies and official resources provide additional scientific context for this peptide:

Liraglutide Research Articles

Compare Liraglutide to alternatives

Side-by-side mechanism, dose, half-life, and vendor pricing.

Open compare →

Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.